FGFR1 Antibody

Product Discontinued

FGFR1 Antibody Summary

• Immunogen: Peptide with sequence CLPRHPAQLANGGLKR corresponding to C-Terminus according to NP_075598.2, NP_056934.2, NP_075593.1, NP_075594.1, NP_075599.1.
• Specificity: This antibody is expected to recognise five isoforms (as represented by NP_075598.2; NP_056934.2; NP_075593.1; NP_075594.1; NP_075599.1).
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FGFR1
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 4 - 6 ug/ml
  • Immunohistochemistry-Paraffin 4 - 6 ug/ml
  • Peptide ELISA Detection limit 1:32000
  • Western Blot 0.3 - 1 ug/ml
• Application Notes: WB: Approx. 75 kDa band observed in human breast lysates (calculated MW of 82.2 kDa band according to NP_075593, 81.9 kDa band according to NP_075594). IHC-P: Human small intestine shows staining of the enterocytic cytoplasm.
• Control:

  FGFR1 Overexpression Lysate

Reactivity Notes

Predicted cross-reactivity based on sequence identity: Canine, Bovine.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris (pH 7.3), 0.5% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.5 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for FGFR1 Antibody

• basic fibroblast growth factor receptor 1
• BFGFR
• bFGF-R-1
• CD331 antigen
• CD331
• CEK
• EC 2.7.10
• EC 2.7.10.1
• FGF R1
• FGFBR
• FGFR1
• FGFR-1
• fibroblast growth factor receptor 1
• FLGH3
• FLJ99988
• Flt-2
• FLT2H4
• Fms-like tyrosine kinase 2
• fms-related tyrosine kinase 2
• H2
• H5
• HBGFR
• heparin-binding growth factor receptor
• hydroxyaryl-protein kinase
• KAL 2
• KAL2
• N-SAM
• OGD
• Proto-oncogene c-Fgr
• soluble FGFR1 variant 1
• soluble FGFR1 variant 2

Background

FGFR1 (fibroblast growth factor receptor 1) is a member of the fibroblast growth factor receptor family containing an Ig-like domain and a tyrosine kinase domain. This receptor has multiple isoforms and is a Type I membrane protein. FGFR1 is a widely expressed membrane receptor, with distinct isoforms expressed in specific tissues. FGFR1 binds fibroblast growth factor and induces mitogenesis and cellular differentiation. Defects in FGFR1 result in Pfeiffer syndrome associated with craniosynostosis. FGFR1 can be modified by phosphorylation and can bind basic/acidic fibroblast factor depending on the receptor isoform. FGFR1 has been shown to interact with N-cadherin and NCAM. Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17-38 kDa) that are potent physiological regulators of growth and differentiation of a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They also have been implicated in pathological conditions such as tumorigenesis and metastasis. To date, the FGF family consists of at least 23 members designated FGF1 through FGF23. Four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg-1(fms-like gene 1)]; FGFR2 [bek (bacterial expressed kinase gene product)]; FGFR3 (cek-2), and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported: soluble, secreted, or possibly cleaved forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed, [e.g. a soluble FGF-binding protein containing the extracellular region of FGFR1 and the secreted form of placental alkaline phosphatase (FRAP1)]. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110- 150 kDa proteins that are constructed of an extracellular ligand binding region with either two (alpha type) or typically three (alpha type) immunoglbulin (Ig)-like domains and an eight amino acid acidic box, a transmembrane region, and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind with a similar affinity several of the FGFs. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGF's binding to cellular FGFRs depend on or is markedly facilitated by the low-affinity interaction of FGF with the polysaccharide component of the cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR1 is highly expressed in developing human tissues including the brain (preferentially in neurons), vascular basement membranes, skin, and bone growth plates. It may be found in most anchorage dependent cells on their membrane and also may be localized around and in nuclei. Pfeiffer syndrome, as well as other disorders of human skeletal development, is the result of a mutation in the extracellular domain of FGFR1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FGFR1 Antibody (NB100-1507)(1)

Publication using NB100-1507

• Torry DS, Mukherjea D, Arroyo J, Torry RJ. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Investig 2003-05-01 [PMID: 12759145]

FAQs for FGFR1 Antibody (NB100-1507). (Showing 1 - 2 of 2 FAQ).

1. I would like to inquire whether you have samples of the following antibodies: NBP1-61338, NB600-1287, NBP1-19481, NBP1-19864; The datasheets for these antibodies show different molecular weights of the detected proteins so its no altogether clear to me which one detects the real protein. To sort this out, we would be using FGFR1-deficient cells and would very much appreciate if you could supply us with small aliquots of these antibodies.
   • FGFR1 has multiple isoforms and is subject to multiple PTM's. The molecular weight can vary greatly depending on experimental conditions and samples used. We fully guarantee all of our products for the listed applications and species. If you cannot get a product to work in an application or species stated on our datasheet, our technical service team will troubleshoot with you to get it to work. If a product still does not work after troubleshooting, you can receive a free of charge replacement product or a full refund. Due to our 100% guarantee, we do not offer free of charge samples of our products. If a smaller sample size is available, it will be listed on our product page.
2. I am working in Multiple sclerosis group and mainly working with mice model and cell culture study. I need FGFR1 antibody against Mice for FACS analysis. If it is available can I get the sample to check with my cells? And any Oligodendrocyte markers against mice for FACS too.
   • We do have an antibody that has been tested in FLOW, NB600-1287, however it has not been tested in mouse. If you would like to test this antibody in mouse samples we have an Innovators Reward Program where we reward you for trying our antibody in species and applications that have not been previously tested.

Bioinformatics

• Gene Symbol: FGFR1
• Entrez:
  • 2260(Human)
• Uniprot:
  • P11362()